clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphadenitis D008199 8 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mastoiditis D008417 2 associated lipids
Metaplasia D008679 7 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Myocardial Infarction D009203 21 associated lipids
Myxoma D009232 1 associated lipids
Nasal Polyps D009298 26 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nocardia Infections D009617 6 associated lipids
Endophthalmitis D009877 12 associated lipids
Psittacosis D009956 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Otitis Media D010033 12 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Pain D010146 64 associated lipids
Pancreatitis D010195 10 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotid Diseases D010305 1 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Parotitis D010309 4 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Periodontal Abscess D010508 2 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Pleural Diseases D010995 4 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Psoriasis D011565 47 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pyelonephritis D011704 5 associated lipids
Radiation Injuries D011832 14 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rodent Diseases D012376 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Morikawa K et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. 1996 Antimicrob. Agents Chemother. pmid:8726002
Arain TM et al. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. 1996 Antimicrob. Agents Chemother. pmid:8726034
Shafran SD et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. 1996 N. Engl. J. Med. pmid:8676931
Shimoyama T et al. Validity of various diagnostic tests to evaluate cure of Helicobacter pylori infection. 1996 J. Gastroenterol. pmid:8680535
Berg-Candolfi M and Candolfi E Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. 1996 Int. J. Parasitol. pmid:9024879
MacConnachie AM Clarithromycin (klaricid, Abbott). 1996 Intensive Crit Care Nurs pmid:8696027
Meier A et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. 1996 J. Infect. Dis. pmid:8699066
Griffith DE et al. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. 1996 Clin. Infect. Dis. pmid:8953085
Sellal A et al. [Maintenance treatment of cerebral toxoplasmosis in AIDS: role of clarithromycin-minocycline combination]. 1996 Presse Med pmid:8685115
Schouenborg P [Clarithromycin]. 1996 Ugeskr. Laeg. pmid:8686028
Pellegrin I et al. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. 1996 J. Antimicrob. Chemother. pmid:9182107
Gisbert JP et al. Response to article by Forné et al. 1996 Am. J. Gastroenterol. pmid:8561132
Steinman MA and Steinman TI Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. 1996 Am. J. Kidney Dis. pmid:8546130
Matsuoka N et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. 1996 Clin. Exp. Immunol. pmid:9099936
Hunt Gerardo S et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. 1996 Antimicrob. Agents Chemother. pmid:8891154
Wintermeyer SM et al. Dirithromycin: a new macrolide. 1996 Ann Pharmacother pmid:8893122
van der Hulst RW et al. Therapeutic options after failed Helicobacter pylori eradication therapy. 1996 Am. J. Gastroenterol. pmid:8931413
Alder JD et al. Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies. 1996 Am. J. Gastroenterol. pmid:8931416
Vilmànyi E et al. Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. 1996 J Small Anim Pract pmid:8934426
Yago K et al. [Protein binding of clarithromycin in patients with chronic renal failure]. 1996 Jpn J Antibiot pmid:8935121
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Aoyama T et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. 1996 J. Pediatr. pmid:8917247
Koeck JL et al. Disseminated Mycobacterium simiae infection in a patient with AIDS: clinical features and treatment. 1996 Clin. Infect. Dis. pmid:8909856
Liviu L et al. Pancreatitis induced by clarithromycin. 1996 Ann. Intern. Med. pmid:8849171
Dammann HG [Helicobacter pylori eradication: triple therapy versus dual therapy]. 1996 Fortschr. Med. pmid:8852685
Cone LA et al. Mania due to clarithromycin therapy in a patient who was not infected with human immunodeficiency virus. 1996 Clin. Infect. Dis. pmid:8853002
Meyboom RH et al. [Possible potentiation of phenprocoumon by clarithromycin and roxithromycin]. 1996 Ned Tijdschr Geneeskd pmid:8628425
Hunt RH Eradication of Helicobacter pylori infection. 1996 Am. J. Med. pmid:8644782
Torriani FJ et al. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. 1996 J. Infect. Dis. pmid:8603975
Vakil N and Fennerty MB Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. 1996 Am. J. Gastroenterol. pmid:8607487
Treiber G The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. 1996 Am. J. Gastroenterol. pmid:8607488
Grau E et al. Interaction between clarithromycin and oral anticoagulants. 1996 Ann Pharmacother pmid:8968465
Muñoz N et al. Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data. 1996 IARC Sci. Publ. pmid:8923024
Dhaenens L et al. In-vitro activities of clarithromycin and other antimicrobial agents against Helicobacter pylori isolated from children. 1996 J. Antimicrob. Chemother. pmid:8877551
Tursi A et al. Helicobacter pylori eradication helps resolve pyloric and duodenal stenosis. 1996 J. Clin. Gastroenterol. pmid:8877648
Thor P et al. Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia. 1996 J. Physiol. Pharmacol. pmid:8877902
Ji B et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. 1996 Antimicrob. Agents Chemother. pmid:8878595
Heifets L Susceptibility testing of Mycobacterium avium complex isolates. 1996 Antimicrob. Agents Chemother. pmid:8843278
Liu W et al. [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592304
Erah PO et al. Ion-pair high-performance liquid chromatographic assay method for the assessment of clarithromycin stability in aqueous solution and in gastric juice. 1996 J. Chromatogr. B, Biomed. Appl. pmid:8832427
Three new studies expand understanding of MAC therapy. 1996 Am J Health Syst Pharm pmid:8899122
Vangala R and Cernek PK Hypersensitivity reaction to clarithromycin. 1996 Ann Pharmacother pmid:8833572
Ji B et al. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. 1996 Antimicrob. Agents Chemother. pmid:8834886
Yamamoto T et al. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. 1996 Antimicrob. Agents Chemother. pmid:8834892
Ji B et al. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? 1996 Antimicrob. Agents Chemother. pmid:8834894
Dattwyler RJ et al. Clarithromycin in treatment of early Lyme disease: a pilot study. 1996 Antimicrob. Agents Chemother. pmid:8834900
Versalovic J et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. 1996 Antimicrob. Agents Chemother. pmid:8834903
Wallace RJ et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. 1996 Antimicrob. Agents Chemother. pmid:8807061
Harford W et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. 1996 Helicobacter pmid:9398875
Schwartz H et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report. 1996 Helicobacter pmid:9398876
Jaup BK Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin. 1996 Helicobacter pmid:9398878
Moayyedi P et al. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. 1996 Helicobacter pmid:9398880
Mégraud F and Malfertheiner P Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995. 1996 Helicobacter pmid:9398889
O'Morain C et al. Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. 1996 Helicobacter pmid:9398893
Lind T et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. 1996 Helicobacter pmid:9398894
van der Hulst RW et al. Treatment of Helicobacter pylori infection: a review of the world literature. 1996 Helicobacter pmid:9398908
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. 1996 AIDS Patient Care STDS pmid:11361534
H. pylori treatment recognized by FDA. 1996 Am J Health Syst Pharm pmid:8725200
Amsden GW Erythromycin, clarithromycin, and azithromycin: are the differences real? 1996 Jan-Feb Clin Ther pmid:8851453
Sander P et al. Ribosomal drug resistance in mycobacteria. 1996 Jan-Feb Res. Microbiol. pmid:8761724
Papp J et al. Efficacy of nizatidine, clarithromycin and bismuth subcitrate therapy for Helicobacter pylori eradication in duodenal ulcer patients--a preliminary report. 1996 Jul-Aug Br J Clin Pract pmid:8794601
Tursi A et al. One-week low-dose triple therapy vs. two-week medium-dose double therapy for H.pylori infection. 1996 Jul-Aug Hepatogastroenterology pmid:8884304
Sketris IS et al. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. 1996 Mar-Apr Pharmacotherapy pmid:8820476
Akamatsu H et al. Enhanced effect of clarithromycin on neutrophil function in vitro. 1996 Mar-Apr J. Int. Med. Res. pmid:8737228
Nightingale SL From the Food and Drug Administration. 1996 May 22-29 JAMA pmid:8622234
Prescott LM Clarithromycin for MAC prevention offers additional benefits. 1996 May-Jun Posit Aware pmid:11363431
Mertl SL The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium-intracellulare infection in patients with AIDS. 1996 May-Jun Pharmacotherapy pmid:8726597
Ono T et al. In vitro and in vivo antibacterial activities of clarithromycin. 1996 May-Jun Chemotherapy pmid:8983882
Peeling RW and Brunham RC Chlamydiae as pathogens: new species and new issues. 1996 Oct-Dec Emerging Infect. Dis. pmid:8969247
Phull PS et al. Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication. 1996 Oct-Nov Br J Clin Pract pmid:9015906
Irie Y et al. Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. 1997 J. Antimicrob. Chemother. pmid:9301989
Rodvold KA et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. 1997 Antimicrob. Agents Chemother. pmid:9174209
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Waites K et al. In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. 1997 South. Med. J. pmid:9191739
Gui GP et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. 1997 J. Antimicrob. Chemother. pmid:9096189
Hoogkamp-Korstanje JA et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. 1997 J. Antimicrob. Chemother. pmid:9096192
Fujii K et al. Multiple primary Mycobacterium avium infection of the skin. 1997 Int. J. Dermatol. pmid:9071619
Martin SJ et al. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. 1997 Diagn. Microbiol. Infect. Dis. pmid:9401809
Sander P et al. The role of ribosomal RNAs in macrolide resistance. 1997 Mol. Microbiol. pmid:9402018
Brancato R et al. Mycobacterium chelonae keratitis after excimer laser photorefractive keratectomy. 1997 Arch. Ophthalmol. pmid:9338681
Yamamoto M et al. [The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection]. 1997 Kekkaku pmid:9038009
Hoppe JE and Tschirner T Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis. 1997 Diagn. Microbiol. Infect. Dis. pmid:9218920
Greco S et al. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. 1997 Ann Pharmacother pmid:9416400
McLaren A et al. The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. 1997 Helicobacter pmid:9432317
Nilius AM et al. Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. 1997 J. Clin. Microbiol. pmid:9163435
Bardhan KD et al. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. 1997 Helicobacter pmid:9432318
Takimoto T et al. The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. 1997 Helicobacter pmid:9432334
Moayyedi P Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin? 1997 Ital J Gastroenterol Hepatol pmid:9513823
Bordet AL et al. [Mycobacterium chelonae cutaneous infection: efficacy of prolonged treatment by clarithromycin]. 1997 Ann Dermatol Venereol pmid:9686059
Lévy M et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. 1997 Gastrointest. Endosc. pmid:9351036
Laine L et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9354200
Rinaldi V et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. 1997 Aliment. Pharmacol. Ther. pmid:9354202
Breuer T et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. 1997 Aliment. Pharmacol. Ther. pmid:9354204
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
Srinivasan R and Minocha A Cure of Helicobacter pylori: a hidden curse? 1997 Am. J. Gastroenterol. pmid:9399784
Different clarithromycin doses affect mortality. 1997 AIDS Patient Care STDS pmid:11361754
Akaki T et al. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. 1997 Kekkaku pmid:9293712
Recker MW and Kier KL Potential interaction between clarithromycin and warfarin. 1997 Ann Pharmacother pmid:9296238
Laberge P and Martineau P Clarithromycin-induced digoxin intoxication. 1997 Ann Pharmacother pmid:9296239
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. 1997 Gut pmid:9301496